Revvity Inc vs TJX Companies Inc — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while TJX Companies Inc trades at $138.86 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 9× Revvity Inc's market cap, and TJX Companies Inc pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and TJX Companies Inc for 97 Days on average.
| RVTY | TJX | |
|---|---|---|
Market Cap | $16.98B | $152.62B |
Volume | 1,456,900 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $168.41 |
52-Week Low | $82.26 | $122.84 |
Typical Hold Time | 12 Days | 97 Days |
Enterprise Value | $19.30B | $160.93B |
Dividend Yield | 0.18% | 1.38% |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
TJX trades at $138.70, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings near 75. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $56.36 billion and $4.86 billion in 2025, respectively, while maintaining a robust ROE of 62.17%.
Wall Street analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 28% upside. Key risks include competitive pressures in off-price retail and potential macroeconomic headwinds affecting consumer spending. The stock's valuation at a P/E of 25.69 appears justified by its earnings growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →